Literature DB >> 31251942

Prediction of maternal and foetal exposures to perfluoroalkyl compounds in a Spanish birth cohort using toxicokinetic modelling.

Céline Brochot1, Maribel Casas2, Cyntia Manzano-Salgado2, Florence A Zeman3, Thomas Schettgen4, Martine Vrijheid2, Frédéric Y Bois3.   

Abstract

Prenatal exposures to perfluorooctanesulfonic acid (PFOS) and perfluorooctanoic acid (PFOA) have been associated with child health outcomes, but many of these associations remain poorly characterized. The aim of this work was to provide new indicators of foetal exposure for the Spanish INMA birth cohort. First, a pregnancy and lactation physiologically based pharmacokinetic (PBPK) model was calibrated in a population framework to provide quantitative estimates for the PFOA and PFOS placental transfers in humans. The estimated distributions indicated that PFOA crosses the placental barrier at a rate three times higher than PFOS and shows a higher variability between mothers. The PBPK model was then used to back-calculate the time-varying daily intakes of the INMA mothers corrected for their individual history from a spot maternal concentration. We showed the importance of accounting for the mothers' history as different dietary intakes can result in similar measured concentrations at one time point. Finally, the foetal exposure was simulated in target organs over pregnancy using the PBPK model and the estimated maternal intakes. We showed that the pattern of PFOA and PFOS exposures varies greatly among the foetuses. About a third has levels of either one compound always higher than the levels of the other compound. The other two thirds showed different ranking of PFOA and PFOS in terms of concentrations in the target organs. Our simulated foetal exposures bring additional information to the measured maternal spot concentrations and can help to better characterize the prenatal exposure in target organs during windows of susceptibility.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Exposure assessment; In utero; PBPK model; PFAS; Pregnancy; Reverse dosimetry

Mesh:

Substances:

Year:  2019        PMID: 31251942     DOI: 10.1016/j.taap.2019.114640

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  4 in total

1.  Modeled prenatal exposure to per- and polyfluoroalkyl substances in association with child autism spectrum disorder: A case-control study.

Authors:  Hyeong-Moo Shin; Deborah H Bennett; Antonia M Calafat; Daniel Tancredi; Irva Hertz-Picciotto
Journal:  Environ Res       Date:  2020-04-14       Impact factor: 6.498

2.  Well-tempered MCMC simulations for population pharmacokinetic models.

Authors:  Frederic Y Bois; Nan-Hung Hsieh; Wang Gao; Weihsueh A Chiu; Brad Reisfeld
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-07-31       Impact factor: 2.745

3.  Integrative Strategy of Testing Systems for Identification of Endocrine Disruptors Inducing Metabolic Disorders-An Introduction to the OBERON Project.

Authors:  Karine Audouze; Denis Sarigiannis; Paloma Alonso-Magdalena; Celine Brochot; Maribel Casas; Martine Vrijheid; Patrick J Babin; Spyros Karakitsios; Xavier Coumoul; Robert Barouki
Journal:  Int J Mol Sci       Date:  2020-04-23       Impact factor: 5.923

4.  Development of a Gestational and Lactational Physiologically Based Pharmacokinetic (PBPK) Model for Perfluorooctane Sulfonate (PFOS) in Rats and Humans and Its Implications in the Derivation of Health-Based Toxicity Values.

Authors:  Wei-Chun Chou; Zhoumeng Lin
Journal:  Environ Health Perspect       Date:  2021-03-17       Impact factor: 9.031

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.